Neonc Technologies Stock Price Dips 0.1%

Shares of the biotech company trading on the Nasdaq fell slightly amid mixed analyst ratings.

Mar. 14, 2026 at 1:48am

Got story updates? Submit your updates here. ›

Shares of Neonc Technologies Holdings, Inc. (NASDAQ:NTHI), a biotech company developing novel molecular technologies for central nervous system diseases, fell 0.1% during mid-day trading on Wednesday. The stock traded as low as $9.30 and closed at $9.41, with 13,768 shares traded, down from the average session volume of 56,570 shares.

Why it matters

Neonc Technologies is a relatively new biotech company that has drawn mixed analyst ratings, with one firm issuing a 'sell' recommendation and another raising the stock to a 'hold' rating. The company's stock price performance and trading volume fluctuations are closely watched by investors as it continues to advance its lead drug candidates through clinical trials.

The details

According to the report, Neonc Technologies' stock price decline came amid lower than average trading volume. The company's lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma, and NEO212, a molecule combining a chemotherapeutic drug with another compound, that has completed preclinical testing.

  • Neonc Technologies' stock price fell 0.1% during mid-day trading on Wednesday, March 14, 2026.

The players

Neonc Technologies Holdings, Inc.

A biotech company developing novel molecular technologies for treating central nervous system diseases, including glioblastoma.

Weiss Ratings

A research firm that issued a 'sell (e+)' rating on Neonc Technologies' shares.

Zacks Research

A research firm that raised its rating on Neonc Technologies' shares to 'hold'.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Neonc Technologies' stock price fluctuations and mixed analyst ratings highlight the challenges and uncertainties facing a relatively new biotech company as it works to advance its pipeline of central nervous system disease treatments through clinical development.